Understanding the impact of comorbidities like cerebrovascular disease and metabolic conditions like metabolic syndrome, diabetes, dyslipidemia, and others on sNFL concentration is required to acknowledge NFL as a tool for personalized medicine in MS, especially in progressive MS. This evidence concerns the gene NEFL and diabetes mellitus.